Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Improved financials
Launch excellence
High-value innovation
Operational excellence
> Strengthen foundations
Conclusion
Abbreviations
Continue to strengthen foundations including
improving access for patients
Broad access to innovation
Material ESG factors
1. Patient health & safety
2. Access
3. Innovation
4. Ethical business
practices
Access
100% of launches with access
strategy (Access Principles)
Innovative pricing and access
models (SSA and EMB)
Sustainability-linked bond targets.
on track (LMICS, 2025):
-
3x patient reach¹ with strategic
innovative therapies
- 1.5x patient reach¹ through
flagship programs
Innovation
Innovative therapies
reaching more LMIC
patients faster
Neglected tropical
diseases
Clinical trial diversity
5. Strengthen foundations
Other priority areas
Human capital:
Diversity targets
Environment: Net zero
by 2040
Ethics: High ethical
standards and zero
tolerance
Leading position in
third-party ESG ratings
1. Results in improved population health and substantial social impact
28
Novartis Investor Presentation | September 22, 2022
1 |
NOVARTIS | Reimagining MedicineView entire presentation